Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 15,300 shares, a decrease of 16.8% from the November 15th total of 18,400 shares. Currently, 1.9% of the company’s shares are short sold. Based on an average trading volume of 44,300 shares, the days-to-cover ratio is currently 0.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Addex Therapeutics in a research report on Wednesday, October 2nd.

Addex Therapeutics Price Performance

ADXN opened at $8.00 on Friday. The company has a market capitalization of $8.48 million, a PE ratio of -23.53 and a beta of 1.74. Addex Therapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $27.90. The business has a 50-day moving average of $9.40 and a 200-day moving average of $9.01.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings data on Monday, September 30th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($1.70). The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.26 million. Addex Therapeutics had a negative return on equity of 112.43% and a net margin of 850.30%. On average, equities research analysts expect that Addex Therapeutics will post 9.8 earnings per share for the current fiscal year.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.